Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia

FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia

(2018) Marielle Perry et al.   Clinical Lymphoma Myeloma & Leukemia

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

(2018) Ann-Kathrin Eisfeld et al.   LEUKEMIA

Detection ofFLT3/TKDandIDH1Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC

(2017) Akbar Ali et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia

(2015) S Wakita et al.   LEUKEMIA

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine

(2015) N Chatain et al.   LEUKEMIA

Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations

(2014) Sheng-Chieh Chou et al.   LEUKEMIA RESEARCH

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

(2014) Hanna Janke et al.   PLoS One

Prevalence and Prognostic Significance of FLT3 Gene Mutations in Patients with Acute Leukaemia: Analysis of Patients from the Shanghai Leukaemia Co-operative Group

(2013) W Wang et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

(2013) M. Levis   Hematology-American Society of Hematology Education Program

Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry

(2012) S Kurosawa et al.   BONE MARROW TRANSPLANTATION

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia

(2012) S Wakita et al.   LEUKEMIA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

(2010) S. Ohtake et al.   BLOOD

Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis

(2008) Mamdooh Gari et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES